If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> <br /> Contents<br /> + EDITORIAL BOARD 4<br /> + WELCOME 7<br /> + FOREWORD 9<br /> + CONGRESS REVIEW<br /> Review of The European Hematology Association (EHA) Congress 2019, 12<br /> held in Amsterdam, the Netherlands, 13th – 16th June, 2019.<br /> + CONGRESS INTERVIEWS<br /> Shai Izraeli 27<br /> Marek Mraz<br /> Barbara Bain<br /> + SYMPOSIUM REVIEW<br /> Rebooting the Myeloma Treatment Programme 36<br /> + ABSTRACT REVIEWS <a title="EMJ Hematology 7.1 2019 page 1" href="http://viewer.zmags.com/publication/e57dbdab?page=1"> </a> <a title="EMJ Hematology 7.1 2019 page 2" href="http://viewer.zmags.com/publication/e57dbdab?page=2"> Contents + EDITORIAL BOARD </a> <a title="EMJ Hematology 7.1 2019 page 3" href="http://viewer.zmags.com/publication/e57dbdab?page=3"> “This year’s EHA congress showcased the very best</a> <a title="EMJ Hematology 7.1 2019 page 4" href="http://viewer.zmags.com/publication/e57dbdab?page=4"> Editorial Board Editor-in-Chief Prof Emili Montse</a> <a title="EMJ Hematology 7.1 2019 page 5" href="http://viewer.zmags.com/publication/e57dbdab?page=5"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ Hematology 7.1 2019 page 6" href="http://viewer.zmags.com/publication/e57dbdab?page=6"> EMJ Hematol. Chief Executive Officer Spencer Gore</a> <a title="EMJ Hematology 7.1 2019 page 7" href="http://viewer.zmags.com/publication/e57dbdab?page=7"> Welcome A very warm welcome to EMJ Hematology 7.1</a> <a title="EMJ Hematology 7.1 2019 page 8" href="http://viewer.zmags.com/publication/e57dbdab?page=8"> + get CML monitoring results for my pati</a> <a title="EMJ Hematology 7.1 2019 page 9" href="http://viewer.zmags.com/publication/e57dbdab?page=9"> Foreword Dear Colleagues, It is with enthusiasm t</a> <a title="EMJ Hematology 7.1 2019 page 10" href="http://viewer.zmags.com/publication/e57dbdab?page=10"> INSEPAR *High-risk AML defined as t-AML or AML</a> <a title="EMJ Hematology 7.1 2019 page 11" href="http://viewer.zmags.com/publication/e57dbdab?page=11"> ABLE TOGETHER The first dual drug advanced lipos</a> <a title="EMJ Hematology 7.1 2019 page 12" href="http://viewer.zmags.com/publication/e57dbdab?page=12"> </a> <a title="EMJ Hematology 7.1 2019 page 13" href="http://viewer.zmags.com/publication/e57dbdab?page=13"> Congress Review Review of the European Hematol</a> <a title="EMJ Hematology 7.1 2019 page 14" href="http://viewer.zmags.com/publication/e57dbdab?page=14"> paediatric haematology, myeloid malignancies, h</a> <a title="EMJ Hematology 7.1 2019 page 15" href="http://viewer.zmags.com/publication/e57dbdab?page=15"> We may have witnessed the discovery of the fir</a> <a title="EMJ Hematology 7.1 2019 page 16" href="http://viewer.zmags.com/publication/e57dbdab?page=16"> Imetelstat: The First Disease-Modifying Drug for </a> <a title="EMJ Hematology 7.1 2019 page 17" href="http://viewer.zmags.com/publication/e57dbdab?page=17"> Not only did voxelotor prove to be efficaciou</a> <a title="EMJ Hematology 7.1 2019 page 18" href="http://viewer.zmags.com/publication/e57dbdab?page=18"> Successful Birth is the Most Common Outcome for </a> <a title="EMJ Hematology 7.1 2019 page 19" href="http://viewer.zmags.com/publication/e57dbdab?page=19"> New Fixed-Duration Targeted Therapy for Chronic </a> <a title="EMJ Hematology 7.1 2019 page 20" href="http://viewer.zmags.com/publication/e57dbdab?page=20"> Astonishing Results from Acute Myeloid Leuk</a> <a title="EMJ Hematology 7.1 2019 page 21" href="http://viewer.zmags.com/publication/e57dbdab?page=21"> Results from Part 1 of CASSIOPEIA: Additio</a> <a title="EMJ Hematology 7.1 2019 page 22" href="http://viewer.zmags.com/publication/e57dbdab?page=22"> NADK Gene New Target for Treating T-Cell </a> <a title="EMJ Hematology 7.1 2019 page 23" href="http://viewer.zmags.com/publication/e57dbdab?page=23"> Hu5F9 and Rituximab Combination Could Treat </a> <a title="EMJ Hematology 7.1 2019 page 24" href="http://viewer.zmags.com/publication/e57dbdab?page=24"> Phase III Study of Venetoclax Shows Improvement </a> <a title="EMJ Hematology 7.1 2019 page 25" href="http://viewer.zmags.com/publication/e57dbdab?page=25"> Benefits of Acalabrutinib for Chronic Lymphocytic </a> <a title="EMJ Hematology 7.1 2019 page 26" href="http://viewer.zmags.com/publication/e57dbdab?page=26"> TRACK MINIMAL RESIDUAL DISEASE Design an Experim</a> <a title="EMJ Hematology 7.1 2019 page 27" href="http://viewer.zmags.com/publication/e57dbdab?page=27"> Congress Interviews Find out more about about </a> <a title="EMJ Hematology 7.1 2019 page 28" href="http://viewer.zmags.com/publication/e57dbdab?page=28"> Q3 Q5 As an Executive Board Member, </a> <a title="EMJ Hematology 7.1 2019 page 29" href="http://viewer.zmags.com/publication/e57dbdab?page=29"> Q8 The most significant leap in the last few y</a> <a title="EMJ Hematology 7.1 2019 page 30" href="http://viewer.zmags.com/publication/e57dbdab?page=30"> Doctor Marek Mraz, MSc, MD, PhD  Assoc. Prof. of </a> <a title="EMJ Hematology 7.1 2019 page 31" href="http://viewer.zmags.com/publication/e57dbdab?page=31"> Q4 Do you think there are the same </a> <a title="EMJ Hematology 7.1 2019 page 32" href="http://viewer.zmags.com/publication/e57dbdab?page=32"> Q8 context of immune niches, induce CD20 to </a> <a title="EMJ Hematology 7.1 2019 page 33" href="http://viewer.zmags.com/publication/e57dbdab?page=33"> Professor Barbara Bain  Imperial College, London,</a> <a title="EMJ Hematology 7.1 2019 page 34" href="http://viewer.zmags.com/publication/e57dbdab?page=34"> "One of the pleasures of haematology is disco</a> <a title="EMJ Hematology 7.1 2019 page 35" href="http://viewer.zmags.com/publication/e57dbdab?page=35"> We want you to write for the </a> <a title="EMJ Hematology 7.1 2019 page 36" href="http://viewer.zmags.com/publication/e57dbdab?page=36"> Rebooting the Myeloma Treatment Programme This s</a> <a title="EMJ Hematology 7.1 2019 page 37" href="http://viewer.zmags.com/publication/e57dbdab?page=37"> Steady Stream and Changing Seas in My</a> <a title="EMJ Hematology 7.1 2019 page 38" href="http://viewer.zmags.com/publication/e57dbdab?page=38"> marker, were observed throughout the treatment se</a> <a title="EMJ Hematology 7.1 2019 page 39" href="http://viewer.zmags.com/publication/e57dbdab?page=39"> The proportion of lenalidomide-refractory patient</a> <a title="EMJ Hematology 7.1 2019 page 40" href="http://viewer.zmags.com/publication/e57dbdab?page=40"> elderly patients (≥85 years) have a significantly </a> <a title="EMJ Hematology 7.1 2019 page 41" href="http://viewer.zmags.com/publication/e57dbdab?page=41"> Big Changes May Arise: Evolution of </a> <a title="EMJ Hematology 7.1 2019 page 42" href="http://viewer.zmags.com/publication/e57dbdab?page=42"> References 1. Palumbo A, Anderson K. </a> <a title="EMJ Hematology 7.1 2019 page 43" href="http://viewer.zmags.com/publication/e57dbdab?page=43"> R/R multiple myeloma (MM) patients: 41. Updat</a> <a title="EMJ Hematology 7.1 2019 page 44" href="http://viewer.zmags.com/publication/e57dbdab?page=44"> Abstract Reviews The EHA congress showcased a pl</a> <a title="EMJ Hematology 7.1 2019 page 45" href="http://viewer.zmags.com/publication/e57dbdab?page=45"> response rate was demonstrated, in which the majo</a> <a title="EMJ Hematology 7.1 2019 page 46" href="http://viewer.zmags.com/publication/e57dbdab?page=46"> Support Grant (NCI Grant P30 CA016672). Dr Nieto </a> <a title="EMJ Hematology 7.1 2019 page 47" href="http://viewer.zmags.com/publication/e57dbdab?page=47"> 1.0 0.8 Probability 0.4 0.6 0.2 0.0 Donor </a> <a title="EMJ Hematology 7.1 2019 page 48" href="http://viewer.zmags.com/publication/e57dbdab?page=48"> Table 1: Characteristics of patients in the study</a> <a title="EMJ Hematology 7.1 2019 page 49" href="http://viewer.zmags.com/publication/e57dbdab?page=49"> injections near the axillary lymph nodes. Vaccine</a> <a title="EMJ Hematology 7.1 2019 page 50" href="http://viewer.zmags.com/publication/e57dbdab?page=50"> Gilteritinib Plus Azacitidine in New</a> <a title="EMJ Hematology 7.1 2019 page 51" href="http://viewer.zmags.com/publication/e57dbdab?page=51"> Gilteritinib+azacytidine CRp </a> <a title="EMJ Hematology 7.1 2019 page 52" href="http://viewer.zmags.com/publication/e57dbdab?page=52"> 120 mg gilteritinib was the chosen dose fo</a> <a title="EMJ Hematology 7.1 2019 page 53" href="http://viewer.zmags.com/publication/e57dbdab?page=53"> Interact with us on social media. </a> <a title="EMJ Hematology 7.1 2019 page 54" href="http://viewer.zmags.com/publication/e57dbdab?page=54"> Umbilical Cord Blood Donation: An Evolving</a> <a title="EMJ Hematology 7.1 2019 page 55" href="http://viewer.zmags.com/publication/e57dbdab?page=55"> London; Saint Mary’s Hospital, Manchester</a> <a title="EMJ Hematology 7.1 2019 page 56" href="http://viewer.zmags.com/publication/e57dbdab?page=56"> New Insights in β-Thalassaemia My </a> <a title="EMJ Hematology 7.1 2019 page 57" href="http://viewer.zmags.com/publication/e57dbdab?page=57"> INTRODUCTION Thalassaemia is a hereditary cause o</a> <a title="EMJ Hematology 7.1 2019 page 58" href="http://viewer.zmags.com/publication/e57dbdab?page=58"> defect, which would quickly result in anaemia.6 M</a> <a title="EMJ Hematology 7.1 2019 page 59" href="http://viewer.zmags.com/publication/e57dbdab?page=59"> receptor IIA linked to the human immunoglobulin G</a> <a title="EMJ Hematology 7.1 2019 page 60" href="http://viewer.zmags.com/publication/e57dbdab?page=60"> treatments such as deferiprone and deferasirox wh</a> <a title="EMJ Hematology 7.1 2019 page 61" href="http://viewer.zmags.com/publication/e57dbdab?page=61"> CRISPR/Cas9 Zinc finger nucleases Le</a> <a title="EMJ Hematology 7.1 2019 page 62" href="http://viewer.zmags.com/publication/e57dbdab?page=62"> 21. Cappellini MD et al. Sotatercept, a </a> <a title="EMJ Hematology 7.1 2019 page 63" href="http://viewer.zmags.com/publication/e57dbdab?page=63"> Retrospective Review of the Role of Abdominal </a> <a title="EMJ Hematology 7.1 2019 page 64" href="http://viewer.zmags.com/publication/e57dbdab?page=64"> physician to develop a refined algorithm to </a> <a title="EMJ Hematology 7.1 2019 page 65" href="http://viewer.zmags.com/publication/e57dbdab?page=65"> defined the severity cut-offs for cytopenias </a> <a title="EMJ Hematology 7.1 2019 page 66" href="http://viewer.zmags.com/publication/e57dbdab?page=66"> RESULTS Descriptive Results Thirty-six patients </a> <a title="EMJ Hematology 7.1 2019 page 67" href="http://viewer.zmags.com/publication/e57dbdab?page=67"> Table 2: Frequency (n, and percentage %) of sever</a> <a title="EMJ Hematology 7.1 2019 page 68" href="http://viewer.zmags.com/publication/e57dbdab?page=68"> CONCLUSION The results of this small, retros</a> <a title="EMJ Hematology 7.1 2019 page 69" href="http://viewer.zmags.com/publication/e57dbdab?page=69"> Eltrombopag-Induced Myelofibrosis in Patients with</a> <a title="EMJ Hematology 7.1 2019 page 70" href="http://viewer.zmags.com/publication/e57dbdab?page=70"> INTRODUCTION Immune thrombocytopenia (ITP) </a> <a title="EMJ Hematology 7.1 2019 page 71" href="http://viewer.zmags.com/publication/e57dbdab?page=71"> > Trials that were performed in children. > Abstr</a> <a title="EMJ Hematology 7.1 2019 page 72" href="http://viewer.zmags.com/publication/e57dbdab?page=72"> Table 1: Studies from 2008 to 2019 that were incl</a> <a title="EMJ Hematology 7.1 2019 page 73" href="http://viewer.zmags.com/publication/e57dbdab?page=73"> Table 1 continued. Author Title Country </a> <a title="EMJ Hematology 7.1 2019 page 74" href="http://viewer.zmags.com/publication/e57dbdab?page=74"> Table 1 continued. Author Title Country </a> <a title="EMJ Hematology 7.1 2019 page 75" href="http://viewer.zmags.com/publication/e57dbdab?page=75"> Identification Records identified through data</a> <a title="EMJ Hematology 7.1 2019 page 76" href="http://viewer.zmags.com/publication/e57dbdab?page=76"> months and 3 patients had MF-3 after 12 months. F</a> <a title="EMJ Hematology 7.1 2019 page 77" href="http://viewer.zmags.com/publication/e57dbdab?page=77"> and differentiation and leads to increased p</a> <a title="EMJ Hematology 7.1 2019 page 78" href="http://viewer.zmags.com/publication/e57dbdab?page=78"> were not performed regularly in all patients, on </a> <a title="EMJ Hematology 7.1 2019 page 79" href="http://viewer.zmags.com/publication/e57dbdab?page=79"> Haematol. 2016;137(2):66-72. 23.</a> <a title="EMJ Hematology 7.1 2019 page 80" href="http://viewer.zmags.com/publication/e57dbdab?page=80"> Are Successful Pregnancies an Achievable Goal in </a> <a title="EMJ Hematology 7.1 2019 page 81" href="http://viewer.zmags.com/publication/e57dbdab?page=81"> expect many years of good quality of life;</a> <a title="EMJ Hematology 7.1 2019 page 82" href="http://viewer.zmags.com/publication/e57dbdab?page=82"> months and the results showed a stabl</a> <a title="EMJ Hematology 7.1 2019 page 83" href="http://viewer.zmags.com/publication/e57dbdab?page=83"> after cessation of TKI therapy. Factors associate</a> <a title="EMJ Hematology 7.1 2019 page 84" href="http://viewer.zmags.com/publication/e57dbdab?page=84"> European Leukemia Net. J Clin Oncol. 2009;27(35):</a> <a title="EMJ Hematology 7.1 2019 page 85" href="http://viewer.zmags.com/publication/e57dbdab?page=85"> A Review of the Different Haematological Par</a> <a title="EMJ Hematology 7.1 2019 page 86" href="http://viewer.zmags.com/publication/e57dbdab?page=86"> a recent cohort study conducted by the Delhi Neon</a> <a title="EMJ Hematology 7.1 2019 page 87" href="http://viewer.zmags.com/publication/e57dbdab?page=87"> 7. Quantitative values of biomarker conce</a> <a title="EMJ Hematology 7.1 2019 page 88" href="http://viewer.zmags.com/publication/e57dbdab?page=88"> Immature to Total Leukocyte Ratio I/T ratio is ca</a> <a title="EMJ Hematology 7.1 2019 page 89" href="http://viewer.zmags.com/publication/e57dbdab?page=89"> NEW MARKERS Serum Amyloid A Serum amyloid A (S</a> <a title="EMJ Hematology 7.1 2019 page 90" href="http://viewer.zmags.com/publication/e57dbdab?page=90"> proteins called damage associated molecular p</a> <a title="EMJ Hematology 7.1 2019 page 91" href="http://viewer.zmags.com/publication/e57dbdab?page=91"> MORE MARKERS IN THE PIPELINE Flow cytometric anal</a> <a title="EMJ Hematology 7.1 2019 page 92" href="http://viewer.zmags.com/publication/e57dbdab?page=92"> of sepsis-induced organ dysfunction. 33. Cri</a> <a title="EMJ Hematology 7.1 2019 page 93" href="http://viewer.zmags.com/publication/e57dbdab?page=93"> Resistant Bilateral Chylous Effusion as a Lat</a> <a title="EMJ Hematology 7.1 2019 page 94" href="http://viewer.zmags.com/publication/e57dbdab?page=94"> 1% basophils, 1% erythroblasts, 2% normoblasts, a</a> <a title="EMJ Hematology 7.1 2019 page 95" href="http://viewer.zmags.com/publication/e57dbdab?page=95"> Table 1: Characteristics of patients with dasatin</a> <a title="EMJ Hematology 7.1 2019 page 96" href="http://viewer.zmags.com/publication/e57dbdab?page=96"> DISCUSSION The presented case details a 21-year-o</a> <a title="EMJ Hematology 7.1 2019 page 97" href="http://viewer.zmags.com/publication/e57dbdab?page=97"> In a study by Hughes et al.,17 frequency, risk fa</a> <a title="EMJ Hematology 7.1 2019 page 98" href="http://viewer.zmags.com/publication/e57dbdab?page=98"> Never miss an update again. J</a>